Oral bexarotene is safe and effective in a phase II-III clinical trial in refractory or persistent early stage CTCL. Duvic, M., Martin, A., Kim, Y., Olsen, E., Wood, G., Yocum, R. AMER SOC HEMATOLOGY. 1999: 659A

View details for Web of Science ID 000083790302976